Summary
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near
Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference.
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
New Strong Sell Stocks for April 28th
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Akebia Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 1 | $3.64 | $1.39 | -$2.25 | -61.81% |
| BG Bart Gancher Intech Investment Management LLC | 66,065 | $152,385.34 | $90,509.05 | -$61,876.29 | -40.61% |
 Blake Harper Orchard Capital Management LLC | 53,510 | $72,917.19 | $73,843.8 | $926.61 | 1.27% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 839,729 | $1.22M | $1.14M | -$77,150.01 | -6.33% |
 Joseph Castro Nuveen LLC | 596,599 | $2.16M | $823,306.62 | -$1.34M | -61.95% |
Akebia Therapeutics Inc. (AKBA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Akebia Therapeutics Inc. ever had a stock split?
Akebia Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | John Butler CEO | NASDAQ (CM) Exchange | 00972D105 CUSIP |
| US Country | 194 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Akebia Therapeutics, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative therapeutics for patients suffering from kidney diseases. Since its incorporation in 2007 and headquartered in Cambridge, Massachusetts, the company has been at the forefront of addressing the comprehensive needs of kidney disease patients through its robust research and development efforts. Akebia Therapeutics engages in strategic collaborations with leading pharmaceutical companies such as Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutica NV to expand its global reach and enhance its R&D capabilities. The company's commitment to improving the quality of life for patients with kidney diseases is reflected in its targeted product development strategy, focusing on delivering treatment options that address unmet medical needs in this domain.
Products and Services
Vafseo (vadadustat): Serving as the company's lead investigational product candidate, Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase currently in Phase III development. It is designed to treat anemia caused by chronic kidney disease (CKD), catering to both dialysis-dependent and non-dialysis dependent patients. Vafseo's innovative mechanism aims to mimic the body's natural response to hypoxia, potentially offering a novel and effective treatment option for this wide patient population.
Auryxia (ferric citrate): Auryxia is a marketed product of Akebia Therapeutics, indicated for the control of serum phosphorus levels in adult patients with dialysis-dependent CKD (DD-CKD). Furthermore, it is used to treat iron deficiency anemia in adult patients suffering from CKD not on dialysis. Through its dual functionality, Auryxia addresses critical aspects of kidney disease management, highlighting Akebia's commitment to providing comprehensive care solutions for patients with kidney-related health issues.
AKB-9090: Akebia Therapeutics' product pipeline includes AKB-9090, a drug under development that targets critical-care indications. Although specific details regarding its mechanism of action and clinical targets are not provided, AKB-9090 represents the company’s ongoing commitment to expanding its portfolio to address more complex and urgent care scenarios within the realm of kidney disease and related conditions.
AKB-10108: Another notable component of Akebia's developmental pipeline is AKB-10108, a drug targeting conditions related to premature birth. While not directly related to kidney disease, this venture into addressing premature birth conditions showcases Akebia Therapeutics' broader interest in tackling significant healthcare challenges that intersect with its core focus on nephrology and patient care across different stages of life.
